Joint-specific sensitivity of FLS and clinical responses in RA to methotrexate and tofacitinib have been observed (17, 25), and it is also possible that responses to TNF inhibitors could be influenced, in part, by joint location. Here, TNF is linked to rheumatoid arthritis.